Market Overview

Analyst Sees 243% Upside For Corbus Pharma Following Positive Clinical Data

Share:
Analyst Sees 243% Upside For Corbus Pharma Following Positive Clinical Data

Shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) gained 10 percent on Thursday in reaction to the company's encouraging update to a phase 2 trial of its autoimmune disease drug called anabasum.

Corbus' top-line data from a 22-patient study of anabasum for the treatment of dermatomyositis demonstrated a "highly clinically meaningful and statistically significant" improvement among patients, Cantor Fitzgerald's Elemer Piros said in a research report. Specifically, the data showed a reduction in CDASI scores from baseline of 9.3 points when treated with anabasum versus 3.7 points for patients who were given a placebo. The data also adds a third clinically validated program to the company's late-stage development pipeline.

Piros maintains an Overweight rating on Corbus' stock with an unchanged $24 price target.

"In addition, encouraging evidence of a dose response was also viewed, where the treatment effect following escalation to 20mg anabasum bid (end of week 4), CDASI improved by 6.3 points (p=0.02)," the analyst also said in the report. "We note that the clinical investigator for the study viewed a five point reduction as clinically meaningful, which was surpassed in the Phase 2 study."

Finally, despite the small size of the study, Corbus' therapy is viewed as a "compelling treatment effect" while additional data and analysis are expected to be detailed at the American College of Rheumatology annual meeting on Nov. 7.

At time of publication, shares of Corbus were up 14. 29 percent at $8.

Related Links:

Three Ways To Approach The Cannabis Trade

From A(erie) To Z(ynerba): Biotech Catalysts Lined Up For Second Half Of 2017

Latest Ratings for CRBP

DateFirmActionFromTo
Mar 2020NomuraInitiates Coverage OnBuy
Apr 2019JefferiesInitiates Coverage OnBuy
Mar 2019OppenheimerInitiates Coverage OnOutperform

View More Analyst Ratings for CRBP
View the Latest Analyst Ratings

 

Related Articles (CRBP)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Long Ideas News Reiteration Analyst Ratings Movers Trading Ideas Best of Benzinga

Latest Ratings

StockFirmActionPT
MRVLCFRAMaintains35.0
CSIQCFRAUpgrades22.0
MGNXSVB LeerinkMaintains27.0
EVCFRAMaintains43.0
RCUSSVB LeerinkReiterates42.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com